Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura2016 · 675 citations
2. 2Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune‐mediated disorders2006 · 114 citations
3. 3The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura2015 · 127 citations
4. 4Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center2011 · 294 citations
5. 5Survival and relapse in patients with thrombotic thrombocytopenic purpura2009 · 577 citations